Core Viewpoint - The introduction of free HPV vaccines in Henan province aims to protect women's health by providing free vaccinations to eligible girls, highlighting the government's commitment to public health and social equity [1][2]. Group 1: Vaccine Introduction - The first batch of 20,000 doses of HPV vaccine has arrived in Zhengzhou, with distribution to local health centers starting immediately [1]. - The HPV vaccine will be included in the national immunization program starting from November 10, 2025, for girls born after November 10, 2011, who are at least 13 years old [1]. Group 2: Vaccine Safety and Efficacy - HPV vaccines have been administered over 1 billion times globally, demonstrating good safety profiles with common mild side effects [2]. - The optimal time for vaccination is around age 13, as it generates a stronger immune response, providing over 90% protection against HPV infections [2]. Group 3: Vaccination Details - Eligible girls must receive two doses of the vaccine, spaced six months apart, ideally completed within 12 months [5]. - Vaccination can be done at local community health service centers, and parental consent is required before the procedure [6]. Group 4: Vaccine Types and Options - The free vaccine provided is a bivalent HPV vaccine targeting types 16 and 18, which are responsible for approximately 70% of cervical cancer cases [4]. - There are also self-paid options available, including quadrivalent and nonavalent vaccines, which cover additional HPV types [7][8].

2月2日中午，一辆装载着特殊"健康礼物"的冷链运输车缓缓驶入漯河市疾病预防控制中心。箱门打开， 冷气微散——里面整齐码放的，正是河南省首批抵达的免费二价HPV疫苗。 从这天起，这样的场景将在全省的各个省辖市陆续上演。河南省疾控中心免疫规划所监测一室主任路明 霞说，预计本周或下周，全省符合条件的女孩就能在家门口的接种门诊，接种上国家送出的这份"健康 防护"了。 这份礼物的背后，是一项温暖而坚定的国家行动。为贯彻落实《加速消除宫颈癌行动计划（2023—2030 年）》，自2025年11月10日起，我国将HPV疫苗正式纳入国家免疫规划，为2011年11月10日以后出生、 年满13周岁的女孩免费接种二价HPV疫苗。 "HPV疫苗纳入国家免疫规划，体现的是健康公平，更是国家对下一代女性健康的郑重承诺。"省疾控中 心免疫规划所所长张延炀说。 此次河南首批到货的疫苗约50万支，来自两个厂家。最近几天，这些疫苗抵达省辖市后，将逐级配送至 全省约3000家预防接种门诊。随着疫苗陆续抵达，许多母亲已开始打电话咨询。一位来自驻马店的妈妈 说："以前觉得打这类疫苗是件遥远的事，现在国家给咱免费了，心里特别踏实。" 据了解，为方便学生 ...

Core Viewpoint - The performance forecasts for A-share vaccine companies in 2025 reveal significant industry adjustments, with major players like Zhifei Biological, Wantai Biological, and Baike Biological reporting losses, while companies like CanSino and Watson Biologics achieve growth through innovative products and overseas market expansion [1][2]. Industry Overview - The vaccine industry is facing multiple pressures, including price wars, shrinking demand, and product homogenization, which are forcing companies to shift from channel-driven to innovation-driven strategies [1][4]. - The overall profitability of the industry has sharply declined, with Zhifei Biological expecting its first annual loss since its listing, projecting a net loss of 10.698 billion to 13.726 billion yuan, a year-on-year decline of 630% to 780% [1][2]. Company Performance - Zhifei Biological, Wantai Biological, and Baike Biological have all transitioned from profit to loss due to various factors, including price cuts and inventory issues [1][2]. - CanSino has turned a profit in 2025, with a projected net profit of 24.5 million to 29 million yuan, benefiting from the strong sales of its four-valent meningococcal vaccine, which accounts for 90% of its revenue [2][6]. - Watson Biologics has seen a 35% year-on-year increase in overseas vaccine exports, achieving a net profit of 16 million to 19 million yuan, reflecting its ability to counter domestic declines [2][7]. Market Dynamics - The ongoing price war is compressing profit margins, with significant price drops observed in various vaccine categories, such as the HPV vaccine and flu vaccine, leading to reduced gross margins for companies [4][8]. - Demand for vaccines is declining due to a falling birth rate and low vaccination rates among adults, exacerbating the industry's growth challenges [4][5]. Strategic Shifts - Companies are increasingly focusing on innovation and overseas expansion as key strategies to navigate the current market challenges [5][9]. - The inclusion of the HPV vaccine in the national immunization program is expected to stabilize market demand but will also pressure companies to reduce costs and innovate further [8][9]. Future Outlook - 2025 is seen as a pivotal year for the vaccine industry in China, with a shift towards high-quality development and a focus on core competencies and innovation [9]. - The industry is expected to gradually recover as innovative products are launched, overseas markets are expanded, and public awareness of vaccination increases [9].

Core Insights - The performance forecasts for A-share vaccine companies in 2025 reveal significant industry adjustments, with major players like Zhifei Biological, Wantai Biological, and Baike Biological reporting losses, while companies like CanSino and Watson Biologics achieve growth through innovative products and overseas market expansion [1][2][5] Industry Overview - The vaccine industry is facing multiple pressures, including price wars and shrinking demand, leading to a significant contraction in profitability [5][6] - The continuous price competition has compressed profit margins, with HPV vaccines and flu vaccines reaching historical lows in pricing, impacting overall industry profitability [5][6] - The decline in birth rates has reduced the core vaccination population for children's vaccines, while adult vaccine uptake remains low due to vaccine hesitancy [5][6] Company Performance - Zhifei Biological is expected to report its first annual loss since its listing, with a projected net loss of 10.698 billion to 13.726 billion yuan, a year-on-year decline of 630% to 780% [1] - Wantai Biological and Baike Biological also shift from profit to loss, with projected net losses of 330 million to 410 million yuan and 220 million to 280 million yuan, respectively [1] - CanSino is projected to turn a profit with a net income of 24.5 million to 29 million yuan, benefiting from the strong sales of its quadrivalent meningococcal vaccine [2] - Watson Biologics expects a net profit of 160 million to 190 million yuan, driven by a 35% increase in overseas vaccine exports [2] Market Dynamics - The industry is experiencing severe product homogeneity, leading to intensified competition among companies in popular vaccine segments like HPV and shingles [6] - Companies overly reliant on agency models are facing challenges, as seen with Zhifei Biological, which has a high dependency on agency products [6] - Inventory and cash flow pressures are evident, with companies like Zhifei Biological and Wantai Biological facing significant inventory write-downs [6] Innovation and Opportunities - Companies with unique innovative products are achieving performance rebounds, with CanSino's quadrivalent vaccine capturing over 90% market share [7] - The overseas market is becoming a crucial growth point, with Watson Biologics exporting to 24 countries and CanSino's inhaled vaccine gaining market share in Southeast Asia and Latin America [8] - The inclusion of the bivalent HPV vaccine in the national immunization program is expected to stabilize market demand while also compressing profit margins for companies [9] Future Outlook - 2025 is seen as a pivotal year for the vaccine industry to transition towards high-quality development, with a focus on innovation and overseas market expansion [10] - The industry is expected to gradually emerge from the adjustment period as innovative products are launched and vaccination awareness increases among residents [10] - The China Vaccine Industry Association has initiated measures to curb irrational price competition, aiming for a more rational pricing environment in the future [10]

Core Viewpoint - The HPV vaccine market is experiencing a significant downturn, with major companies facing operational challenges and financial losses as they transition from rapid growth to a more competitive landscape [1][2]. Group 1: Company Performance - Zhifei Biological is projected to incur a net loss of 10.698 billion to 13.726 billion yuan in 2025, marking a staggering decline of 630% to 780% year-on-year [4][6]. - Wantai Biological anticipates its first annual net loss since going public, estimated between 330 million to 410 million yuan [4][2]. - Watson Biological expects a net profit of 160 million to 190 million yuan in 2025, reflecting a year-on-year growth of 13% to 34%, although its net profit excluding non-recurring items is projected to decline by 9% to 22% [2][4]. Group 2: Market Dynamics - The HPV vaccine market is facing intense competition, leading to price wars as companies attempt to gain market share amid declining demand and increasing product homogeneity [1][8]. - Zhifei Biological is burdened with over 20 billion yuan in inventory, with a significant portion of its nine-valent vaccines set to expire in 2026, raising concerns about potential write-offs [7][8]. - Wantai Biological's sales of its bivalent vaccine have been adversely affected by the approval of competing products and the expansion of the nine-valent vaccine's age range, leading to a sharp decline in revenue and profit [8][9]. Group 3: Strategic Responses - Companies are adjusting their strategies to cope with market pressures, including optimizing procurement plans, enhancing product promotion strategies, and improving inventory turnover efficiency [7][16]. - Wantai Biological and Watson Biological are targeting the public procurement market to stabilize their positions, with significant price reductions for their bivalent vaccines [12][15]. - The industry is urged to shift from a price-driven approach to one focused on quality, technological upgrades, brand building, and international expansion to overcome current challenges [16].

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The vaccine industry is currently facing short-term performance pressure due to weak demand and structural oversupply, with many companies experiencing declines or losses in performance [1][7][8] - Despite the challenges, innovation and international expansion are ongoing, providing potential for medium to long-term growth [1][8] - The industry is transitioning from scale expansion to innovation-driven growth, with policy, demand, and technology as the three main driving factors for development [8][24][26] Summary by Sections Domestic and International Vaccine Dynamics - Kanghua Biotech has initiated Phase I clinical trials for its six-valent norovirus vaccine, which theoretically can prevent over 90% of norovirus infections [1] - Wantai Biopharma's bivalent HPV vaccine has successfully passed the WHO PQ periodic review [1] - Zhifei Biological's application for clinical trials of a freeze-dried inactivated vaccine for Japanese encephalitis has been accepted [1] Performance Forecasts - Chengda Bio expects a 59.34%-63.98% decrease in net profit for 2025 compared to the previous year [1] - CanSino anticipates a revenue increase of 22.88%-27.61% for 2025, with a turnaround in net profit [1] - Watson Bio forecasts a revenue of 2.4-2.43 billion yuan for 2025, a decline of approximately 14.9%-13.9% [1] - Other companies like Kangtai Bio and Wantai Bio also expect significant declines in net profit for 2025 [1] Market Performance - The vaccine sector saw a decline of 1.65% last week, with the overall pharmaceutical industry down 3.31% [2][5] - The vaccine sector has experienced a cumulative decline of 10.08% since the beginning of 2025 [5][13] Valuation Metrics - The vaccine sector's PE (ttm) is 92.01X, down 1.88X from the previous week, while the PB (lf) is 1.78X, down 0.04X [6] - The PE is at the 55.99% percentile since 2013, and the PB is at the 1.28% percentile since 2013 [6] Investment Recommendations - The vaccine industry is still under pressure, but companies are actively adjusting their pipeline strategies, focusing on technological innovation and multi-valent products [7][8] - Long-term prospects remain positive due to innovation and international market expansion, with a recommendation to focus on companies with strong R&D capabilities and differentiated product offerings, such as CanSino [8][26]

Group 1: Company Announcements - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder post-restructuring [1] - Silver Industry's gold and silver product revenues are low, with gold sales contributing 18.67% and silver 4.54% to total revenue in H1 2025 [2] - Tianneng Wind Power has decided to implement long-term production halts for six wholly-owned subsidiaries to optimize resource allocation and focus on core offshore wind power business [3] Group 2: Price and Supply Risks - Tongling Nonferrous Metals reports significant uncertainty in the prices of cathode copper and other main products, with low self-sufficiency in copper concentrate posing supply stability risks [4] - ST Aowei received a notice of termination of listing due to market capitalization falling below 500 million yuan for 20 consecutive trading days [5][6] Group 3: Performance Forecasts - Foton Motor expects a net profit increase of approximately 1551% to around 1.33 billion yuan in 2025, driven by sales growth across various segments [7] - Beimo High-Tech anticipates a net profit of 190 million to 220 million yuan, reflecting a growth of 1076.16% to 1261.87% [8] - Zhongke Sanhuan forecasts a net profit increase of 566.23% to 899.35%, driven by cost control and market expansion [9] - Wancheng Group expects a net profit of 1.23 billion to 1.4 billion yuan, a growth of 222.38% to 266.94% [10] - Wan Yi Technology anticipates a net profit increase of 191.52% to 330.34%, supported by product optimization and cost reduction measures [11] - Nanmo Biology expects a net profit of 24 million to 34 million yuan, a growth of 269.49% to 423.44% [12] - Bai'ao Saitou forecasts a net profit increase of 384.26% to 443.88%, benefiting from overseas market expansion [13] - Hailanxin anticipates a net profit of 40 million to 60 million yuan, a growth of 387.47% to 631.2% [14] - Panzhihua Coal expects a net profit of 318 million to 380 million yuan, a growth of 205.3% to 264.83% [15] - Huaguang New Materials forecasts a net profit increase of 104.67% to 141.88% [16] - Putian Technology expects a net profit of 1.92 million to 2.88 million yuan, a growth of 71.55% to 157.33% [17] - Guoda Special Materials anticipates a net profit increase of 82.61% [18] - Tongkun Co. expects a net profit of 1.95 billion to 2.15 billion yuan, a growth of 62.24% to 78.88% [19] - Yiming Pharmaceutical forecasts a net profit increase of 61.12% to 122.08% [20] - Guosheng Securities expects a net profit of 210 million to 280 million yuan, a growth of 25.44% to 67.25% [21] - Shengyi Technology anticipates a net profit increase of 87% to 98% [22] Group 4: Loss Forecasts - Saifutian expects a loss of 30 million to 45 million yuan, significantly reducing previous losses [23] - Magang Group forecasts a loss of 190 million to 250 million yuan, a substantial reduction in losses [24] - Shennong Seed Industry anticipates a profit of 90 million to 120 million yuan, reversing previous losses [25] - Jifeng Co. expects a profit of 410 million to 495 million yuan, reversing previous losses [26] - Bingchuan Network forecasts a profit of 436 million to 516 million yuan, reversing previous losses [27] - Zhongyou Technology anticipates a profit of 540 million to 640 million yuan, reversing previous losses [28] - Dongfang Biology expects a loss of 523 million yuan [29] - Wantai Biological anticipates a loss of 330 million to 410 million yuan due to market pressures [30] - Anbotong expects a loss of 114 million to 165 million yuan [31] - Shunxin Agriculture forecasts a loss of 116 million to 188 million yuan due to declining sales [32] - Guozhong Water expects a loss of 130 million to 104 million yuan, with potential delisting risks [33] Group 5: Major Contracts - China Communication Signal expects to win 21 major projects worth approximately 5.26 billion yuan [34]

2026.01. 29 本文字数：1466，阅读时长大约3分钟 作者 | 第一财经 林志吟 中国人用疫苗（下称疫苗）出口金额在2024年恢复正增长后，2025年再度出现增长，且增速进一步 提高。 中国医药保健品进出口商会1月29日在公众号上发布的数据显示，2025年，中国疫苗出口金额为 3.24亿美元，同比增长52.63%。 回顾2024年，中国疫苗出口金额为2.12亿美元，同比增长4.92%，彼时是2022年以来首次恢复正 增长，摆脱了过去三年受抗击新冠疫情需求变化而带来的波动影响。 2025年，中国人用疫苗出口到了全球85个市场，前十大市场出口金额占比为70.04%。其中，对巴 基斯坦出口同比增长130.53%，对巴西出口同比增长为119.50%，对缅甸出口增幅甚至高达近30 倍。 长期以来，国内许多疫苗企业聚焦成熟度高且市场风险较小的传统技术路线产品，Me-too（同类仿 创）类管线占比高，且大多集中在宫颈癌疫苗、肺炎球菌疫苗和脑膜炎球菌疫苗等热门疫苗品种，重 磅产品上市时间显著晚于欧美头部企业，进而导致国内疫苗存量市场竞争持续加剧、产品同质化竞争 日益明显。 面对国内疫苗市场竞争愈演愈烈背景下，越来越 ...

2025年，中国疫苗出口到了全球85个市场。 沃森生物（300142.SZ）在1月28日晚间发布的2025年业绩预告中表示，公司国内疫苗产品收入降幅收 窄，趋于平稳，国外疫苗产品收入持续增长，出口疫苗产品收入较上年同期增长约35%。 不过，中国疫苗企业在加大出口的过程中，如何获得更高利润回报，目前仍有待发力。相较2024年疫苗 出口金额靠价格驱动的增长，2025年的出口更多还是靠量取胜。2025年，疫苗出口量增幅高达 130.54%，显示出"量增价跌"的趋势。 长期以来，国内许多疫苗企业聚焦成熟度高且市场风险较小的传统技术路线产品，Me-too（同类仿创） 类管线占比高，且大多集中在宫颈癌疫苗、肺炎球菌疫苗和脑膜炎球菌疫苗等热门疫苗品种，重磅产品 上市时间显著晚于欧美头部企业，进而导致国内疫苗存量市场竞争持续加剧、产品同质化竞争日益明 显。 面对国内疫苗市场竞争愈演愈烈背景下，越来越多的中国疫苗企业加大力度往外走，一些企业借助"一 带一路"沿线国家产业合作机遇，加大海外发展中国家或地区的市场布局力度。在"一带一路"国家中， 不少发展中国家缺乏疫苗生产能力，这给中国疫苗企业出海发展带来机遇。 康泰生物（3006 ...

根据公告，业绩变动主要系二价HPV疫苗产品受多重因素影响，出现近效期无法销售及库存减值，预计 影响净利润5—6亿元左右。同时，九价HPV疫苗尚处于市场准入阶段，利润贡献尚未充分体现。此外， 诊断板块亦受集采降价及医保政策影响，收入利润同比下滑。 北京商报讯(记者王寅浩宋雨盈)1月29日，万泰生物（603392）发布2025年业绩预告，预计2025年归属 于母公司所有者的净亏损为3.3亿—4.1亿元，同比转亏。预计实现归属于母公司所有者的扣除非经常性 损益的净亏损为5.3亿—6.6亿元。 ...